The FDA approval of RASONQUE (daraxonrasib, code RMC-6236) marks the official transition of RAS-targeted therapy from a single mutation subtype (G12C) into the era of 'multi-selective' inhibition. But for the research community, this is only the first domino in a much larger arrangement. From finer segmentation of mutation subtypes to combinations with chemotherapy and immunotherapy, competition in the RAS field is just beginning to heat up.
Subtype Refinement: G12D Is the Next Decisive Battleground
Within the landscape of RAS mutations, KRAS G12D is the most common subtype in pancreatic cancer (accounting for about 40%) and also represents a significant proportion of colorectal cancers. Daraxonrasib is a 'multi-selective' inhibitor that can simultaneously cover multiple subtypes such as G12D, G12V, and G12R; meanwhile, 'selective' inhibitors targeting G12D (such as zoldonrasib / RMC-9805) are also showing activity in clinical trials. Future treatment decisions will likely rely on genetic testing results to make precise choices between multi-selective and subtype-selective drugs—which is why comprehensive next-generation sequencing (NGS) reports are becoming increasingly important.
Combination Therapy and Earlier Lines of Treatment
After the success of monotherapy, the next question naturally becomes 'can we do better, and can we treat earlier?' Ongoing studies include: combining RAS(ON) inhibitors with standard chemotherapy (such as gemcitabine plus albumin-bound paclitaxel) for first-line treatment of pancreatic cancer; combining with immune checkpoint inhibitors to try to convert 'cold tumors' into 'hot tumors' that respond to immunotherapy; and in lung cancer, phase III trials challenging first-line treatment. If these trials succeed, RAS inhibitors will move from 'later-line rescue' to a component of 'initial therapy'.
Resistance research is also underway in parallel. Scientists have observed escape mechanisms such as secondary RAS mutations and bypass signaling activation in both laboratory models and patient samples. Next-generation drugs and 'rotation' strategies are being designed with the goal of slowing down resistance and ensuring there are options when it does occur.
What Does This Mean for Hong Kong Patients?
For patients and families, there are three practical actions: First, ensure that genetic testing covering KRAS subtypes has been done and keep the report. Second, if standard treatments have limited effect, proactively discuss clinical trial options with your oncologist—several hospitals in Hong Kong are continuously enrolling for international multicenter trials targeting RAS-mutant solid tumors. Third, regularly follow research progress. The study recruitment page on this site automatically syncs the latest clinical trials in Hong Kong every two weeks, allowing you to filter by cancer type and mutation gene to find suitable opportunities.